As the race to dominate the artificial intelligence (AI) space steps up a gear, I take a look at how AI finds use in pharma and how different regions plan to invest in this exciting area.
The skills gap is considered one of the greatest challenges facing the UK's life science and medtech sectors today. An initiative from the University of Leicester aims to address the problem. Dave Gray tells us more…
The ability of animal studies to predict human safety has been evaluated by global information analytics business, Elsevier, through big data analysis of adverse events reported to the US FDA and EMA
Biosimilar entry onto US market is slow despite implementation of the Biologics Price Competition and Innovation Act (BPCIA) by the Food and Drug Administration (FDA), according to data and analytics company, GlobalData.
Data and analytics company, GlobalData, has revealed that biosimilars to Humira will have significant uptake across Europe this year as a result of 10–20% lower prices compared with the originator brand.
A new research paper has been released by Siemens Financial Services (SFS), describing ‘CFO 4.0’, which is the new breed of chief financial officer in the manufacturing industry that needs to drive and enable the digital transformation process.
The ‘Life Sciences Industrial Strategy: Who’s driving the bus?’ report has been published by the House of Lords Science and Technology Committee, recommending that the government should simplify its implementation arrangements.
To mark World Malaria Day, the founder of specialist smartphone diagnostics company Novarum DX and BBI Group head of mobile, Dr Neil Polwart, has spoken out to highlight the importance of new diagnostic technologies in tackling the spread of malaria
A new poll from YouGov has revealed that the majority of the British public will personally step up to help the NHS advance medical research and fight diseases of the future.
A new study from the University of Eastern Finland, published in the European Journal of Clinical Pharmacology, has highlighted that there are differences in the availability of orphan medicines between different European countries.
According to a new report from the manufacturers’ organisation, EEF, and AIG has revealed that nearly half of manufacturers have been the victim of cyber-crime with a quarter suffering some financial loss or disruption to business as a result.
